Albireo Pharma Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma or view top-rated stocks.

3 Wall Street analysts have issued 1-year price objectives for Albireo Pharma's stock. Their ALBO stock forecasts range from $66.00 to $80.00. On average, they expect Albireo Pharma's share price to reach $72.67 in the next year. This suggests a possible upside of 276.9% from the stock's current price.
View analysts' price targets for Albireo Pharma or view top-rated stocks among Wall Street analysts.

Albireo Pharma's stock was trading at $23.29 at the beginning of the year. Since then, ALBO shares have decreased by 17.2% and is now trading at $19.28.
View the best growth stocks for 2022 here.

Albireo Pharma saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 1,530,000 shares, an increase of 35.4% from the May 31st total of 1,130,000 shares. Based on an average trading volume of 287,700 shares, the days-to-cover ratio is presently 5.3 days. Approximately 17.1% of the company's shares are short sold.
View Albireo Pharma's Short Interest.

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Albireo Pharma.

Albireo Pharma, Inc. (NASDAQ:ALBO) released its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($2.02) by $0.17. Albireo Pharma had a negative net margin of 72.02% and a negative trailing twelve-month return on equity of 73.93%. During the same quarter in the previous year, the company earned ($2.29) EPS.
View Albireo Pharma's earnings history.

Some companies that are related to Albireo Pharma include Cryoport (CYRX), Axsome Therapeutics (AXSM), BELLUS Health (BLUSF), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Sierra Oncology (SRRA), Day One Biopharmaceuticals (DAWN), Zentalis Pharmaceuticals (ZNTL), Madrigal Pharmaceuticals (MDGL), Prothena (PRTA), Agios Pharmaceuticals (AGIO), Myovant Sciences (MYOV), Cassava Sciences (SAVA), IVERIC bio (ISEE) and Reata Pharmaceuticals (RETA).
View all of ALBO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.94%), Chicago Capital LLC (5.23%), Vanguard Group Inc. (5.05%), State Street Corp (4.69%), Decheng Capital Management III Cayman LLC (2.68%) and Prosight Management LP (2.48%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends for Albireo Pharma.

ALBO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Platinum Investment Management Ltd., Citigroup Inc., Prosight Management LP, Privium Fund Management B.V., BlackRock Inc., and Bank of America Corp DE. Company insiders that have sold Albireo Pharma company stock in the last two years include Jan Mattsson, Jason Duncan, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Ronald Harold Wilfred Cooper, and Simon NR Harford.
View insider buying and selling activity for Albireo Pharma or view top insider-selling stocks.

ALBO stock was acquired by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, Nicholas Investment Partners LP, Chicago Capital LLC, Prudential Financial Inc., MAI Capital Management, Endurant Capital Management LP, Vanguard Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Albireo Pharma or or view top insider-buying stocks.

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALBO stock can currently be purchased for approximately $19.28.

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $373.26 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34.03 million in net income (profit) each year or ($1.76) on an earnings per share basis.

Albireo Pharma employs 130 workers across the globe.

Albireo Pharma was founded in 2003.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for Albireo Pharma is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at [email protected], or via fax at 203-796-5001.